Veradermics has announced positive topline results from Part A of Study 304, its randomised, double blind, placebo controlled, registration directed Phase 3 trial of VDPHL01 in male pattern hair loss. The trial enrolled 536 men with mild to moderate pattern hair loss, randomised to VDPHL01 8.5 mg once daily, 8.5 mg twice daily, or placebo. The company said the trial met all primary and secondary endpoints with high statistical significance, with rapid onset of activity and robust increases in hair count, and was generally well tolerated, with no treatment related serious adverse events and no adverse events of special interest of cardiac origin.
VDPHL01 is a proprietary extended release tablet of minoxidil, a drug dermatology has borrowed from cardiology for decades. Immediate release oral minoxidil is used off label at low doses, but its sharp peak concentrations are the reason it was never developed or approved for hair loss. The extended release design aims to hold exposure above the hair growth threshold while avoiding the peaks, and the absence of cardiac events of special interest in a 536 man controlled trial is the safety half of that argument.
Combined with Part A of the earlier Phase 2/3 Study 302, Veradermics now has six month placebo controlled data in more than 1,000 participants. In Study 302, once daily VDPHL01 raised mean non vellus hair count by 30.3 hairs per square centimetre at six months against 7.3 on placebo, and 79.3 percent of once daily patients reported improved coverage against 35.6 percent on placebo. The company positions VDPHL01 to become the first FDA approved oral pill for pattern hair loss in nearly 30 years, in a US male market it sizes at 50 million men, with a women’s trial, Study 306, also recruiting.
The gap in today’s release is granularity: the topline announcement asserts significance across endpoints without publishing Study 304’s own hair count deltas, which investors were walked through on the company’s October 19 call. The filing case now rests on the full dataset matching Study 302’s effect sizes, and on the cardiac record staying clean as exposure grows.